Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

Completed

Conditions studied: Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia, Primary Progressive Aphasia, Parkinson' Disease Dementia, Mixed Dementia

In brief

The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients having memory impairments.

Key facts

Study ID

NCT01465360

Run by

Exonhit

People needed

160

Starts

2011-11-01

Last updated by the study team

2012-07-06

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patient referred to the center for memory impairment.
• The memory impairment has previously been observed by a caregiver or documented by a physician.
• The memory impairment is confirmed by the memory center.
• Caucasian ethnicity.
• A written informed consent approved by an ethical review board or similar body must be obtained from the patient prior to any study-related procedures.
• If applicable, standard treatment with cholinesterase inhibitor and/or memantine is acceptable.
• Patient estimated to be compliant with study procedures.
• Patient has a level of understanding sufficient to agree to all procedures required by the protocol and must be able to cooperate. Under no circumstances will a subject who does not understand the procedure, be allowed to consent to the procedure.

You may not qualify if…

• Recent acute pathology or medical condition or surgery which may alter the inflammatory homeostasis, according to the opinion of the investigator.
• Non-Caucasian ethnicity.
• Patient with severe uncontrolled or unstable medical condition.
• Need for a legal representative for the medical condition of the patient.
• Any current pathology or medical condition, for which blood sampling may involve a risk for the patient's health, according to the opinion of the investigator.
• Current or recent history (within one month) of clinically significant pathology, medical condition (including hospitalization) or symptoms. However, chronic diseases or medical conditions that are considered stable are accepted, provided that they are compatible with other study selection criteria.
• Current or recent history of drug or alcohol abuse or dependence.
• Current, clinically significant major psychiatric disorder (eg, major depressive disorder) according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition text revised (DSM-IV TR), or significant symptoms (eg, hallucinations).
• Woman of childbearing potential is not allowed to participate in the study. (A woman of childbearing potential is a woman who is biologically capable of becoming pregnant).
• Current participation in another study using an investigational non-marketed product.

Where it is running

• Cleveland Clinic Lou Ruvo Center for Brain Health — Las Vegas, Nevada, United States
• Cleveland Clinic Center for Brain Health - Mellen Center — Cleveland, Ohio, United States
• Cleveland Clinic Senior Care Assessment - Lakewood Hospital — Lakewood, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.